SAVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SAVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cassava Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $137.47 Mil. Cassava Sciences's Total Assets for the quarter that ended in Dec. 2023 was $151.66 Mil.
The historical rank and industry rank for Cassava Sciences's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Cassava Sciences was 0.98. The lowest was 0.90. And the median was 0.96.
The historical data trend for Cassava Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cassava Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.94 | 0.98 | 0.95 | 0.97 | 0.91 |
Cassava Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.97 | 0.94 | 0.91 | 0.90 | 0.91 |
For the Biotechnology subindustry, Cassava Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cassava Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cassava Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cassava Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 137.468 | / | 151.663 | |
= |
Cassava Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 137.468 | / | 151.663 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cassava Sciences (NAS:SAVA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Cassava Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Sanford Robertson | director | ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129 |
Richard Barry | director | 285 MARGALITA DRIVE, SAN RAFAEL CA 94901 |
Robert Christopher Cook | officer: SVP & General Counsel | 6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731 |
James William Kupiec | officer: Chief Clinical Dev. Officer | 7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731 |
Eric Schoen | officer: Chief Financial Officer | 7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731 |
Remi Barbier | director, 10 percent owner, officer: CEO, Chairman of the Board | |
Armistice Capital Master Fund Ltd. | 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
O Donnell Michael J | director | |
Robert Z Gussin | director | |
Scannon Patrick J Md Phd | director | C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710 |
Saira Ramasastry | director | 501 CANAL BLVD., RICHMOND CA 94804 |
Nadav Friedmann | director, officer: Chief Scientific Officer | |
Sabretooth Master Fund, L.p. | 10 percent owner | 405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174 |
From GuruFocus
By PRNewswire • 11-03-2023
By Marketwired • 11-06-2023
By Stock market mentor Stock market mentor • 02-08-2023
By Marketwired • 10-05-2023
By Marketwired • 07-05-2023
By Marketwired • 10-25-2023
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 06-12-2023
By Marketwired • 07-08-2023
By Marketwired • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.